Neurocrine Biosciences 将来の成長
Future 基準チェック /46
Neurocrine Biosciences利益と収益がそれぞれ年間23.1%と11.8%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に20.9% 21.6%なると予測されています。
主要情報
23.1%
収益成長率
21.59%
EPS成長率
| Biotechs 収益成長 | 25.2% |
| 収益成長率 | 11.8% |
| 将来の株主資本利益率 | 20.95% |
| アナリストカバレッジ | Good |
| 最終更新日 | 29 Jun 2026 |
今後の成長に関する最新情報
Recent updates
ナラティブの更新 • Jun 24
NBIX: Future Upside Will Rely On Expanding Rare Disease Franchise
Analysts have nudged their price target for Neurocrine Biosciences higher to $243.06 from $241.76, citing updated views on revenue growth, profit margins, and future P/E expectations following recent coverage initiations and the addition of Soleno Therapeutics' Vykat XR to the portfolio. Analyst Commentary Recent Street research on Neurocrine Biosciences highlights a generally constructive tone, with several firms updating views on the stock following the completion of the Soleno Therapeutics acquisition and fresh coverage initiations.分析記事 • Jun 19
Neurocrine Biosciences (NBIX) Stock Could Be 18% Undervalued After ENDO 2026 CRENESSITY Data
Neurocrine Biosciences (NBIX) is in focus after new CRENESSITY data at ENDO 2026 highlighted hormone normalization in classic CAH due to 11ß hydroxylase deficiency, alongside two-year cardiometabolic and bone health outcomes in adults. See our latest analysis for Neurocrine Biosciences. At a share price of $158.29, Neurocrine Biosciences has given investors a 23.97% 90 day share price return and a 25.08% 1 year total shareholder return, pointing to momentum that has built alongside ENDO 2026...
ナラティブの更新 • Jun 09
NBIX: Future Upside Will Depend On Rare Disease Portfolio Execution
Analysts have lifted the fair value estimate for Neurocrine Biosciences by about $6 to $192.88, reflecting updated views on revenue growth, profitability and valuation after the Soleno acquisition, along with recent Street research highlighting a long runway for key drugs and additional contributions from Vykat XR. Analyst Commentary Recent Street research around Neurocrine Biosciences has been broadly constructive, with several firms updating models after the Soleno acquisition and new readthroughs on key products.
ナラティブの更新 • May 26
NBIX: Pipeline Execution And Integration Risks Will Shape Balanced Future Returns
Analysts lifted their fair value target for Neurocrine Biosciences by about $3 to $144, citing updated assumptions for revenue growth of 14.83%, a profit margin of 18.43%, and a recalibrated future P/E of 21.28x that reflects confidence in the long runway of its key approved drugs and potential contributions from Crenessity and osavampator. Analyst Commentary Recent Street research on Neurocrine Biosciences highlights a mix of optimism around the company’s approved therapies and emerging pipeline, alongside selective caution on execution and valuation.分析記事 • May 08
Neurocrine Biosciences, Inc. Just Recorded A 61% EPS Beat: Here's What Analysts Are Forecasting Next
Neurocrine Biosciences, Inc. ( NASDAQ:NBIX ) investors will be delighted, with the company turning in some strong...ナラティブの更新 • May 07
NBIX: Future Upside Will Depend On Execution Across Two Core Franchises
The updated analyst price target for Neurocrine Biosciences moves to $241.76 from $203.91, with analysts pointing to higher modeled revenue growth and slightly richer future P/E assumptions, partly balanced by a modestly lower profit margin outlook and a small change in the discount rate. Analyst Commentary Recent Street research on Neurocrine Biosciences shows a cluster of price target changes and fresh coverage that tilt bullish overall, even with a few modest trims.Seeking Alpha • May 06
Neurocrine Biosciences: Core Business On Track, Soleno Deal Adds Risky Upside
Summary Neurocrine Biosciences delivered a strong Q1, with revenue up 42% and healthy growth in Ingrezza and Crenessity. Enhanced sales efforts could drive Ingrezza upside in 2H'26, while Crenessity has a long runway for patient adoption, particularly in adults. The $2.9 billion Soleno acquisition brings Vykat XR, a high-potential offering with clear commercial synergies but significant unknowns around long-term patient uptake and compliance. My fair value estimate for NBIX rises to just under $206/share, supported by multiyear upside in Ingrezza, Crenessity, and a promising, though long-dated, pipeline. I maintain a bullish stance on NBIX, seeing the market undervaluing core franchises and risk-adjusted pipeline upside despite tempered guidance. Read the full article on Seeking Alphaナラティブの更新 • Apr 21
NBIX: Future Upside Will Hinge On Tardive Dyskinesia Franchise Execution
The updated analyst price target for Neurocrine Biosciences increases to $186.45 from $178.04. Analysts attribute the change to more supportive long-term earnings expectations and higher assumed future P/E multiples, even as they refine revenue growth and margin assumptions.ナラティブの更新 • Apr 07
NBIX: Mixed 2026 Guidance And Policy Risks Will Shape Future Returns
Analysts have made a small upward adjustment to the fair value estimate for Neurocrine Biosciences to about $140.54, reflecting updated price targets that weigh mixed revisions across the Street against generally constructive views on Ingrezza and Crenessity. Analyst Commentary Street research around Neurocrine Biosciences has been active, with a mix of supportive views on key assets like Ingrezza and Crenessity and a series of price target tweaks that pull in different directions.ナラティブの更新 • Mar 24
NBIX: Future Upside Will Depend On Crenessity Adoption And Pipeline Progress
Analysts have trimmed the blended price target for Neurocrine Biosciences slightly to about $178, reflecting modest tweaks to growth, discount rate and P/E assumptions, while incorporating mixed but generally constructive views on Ingrezza and Crenessity uptake from recent research updates. Analyst Commentary Street research on Neurocrine Biosciences has been active, with several firms adjusting price targets and models around recent earnings, updated guidance and new information on Ingrezza and Crenessity.ナラティブの更新 • Mar 09
NBIX: 2026 Guidance Execution And CAH Competition Will Shape Future Returns
Analysts have kept the fair value estimate for Neurocrine Biosciences steady at $140, while revising their models slightly to reflect updated revenue growth, margins, and P/E assumptions following recent earnings, guidance, and a mix of modest price target cuts and a fresh $160 Outperform initiation. Analyst Commentary Across recent research, you are seeing a mix of optimism around the pipeline and commercial assets along with a cluster of more cautious valuation resets.ナラティブの更新 • Feb 23
NBIX: Execution On 2026 Guidance And Competitive CAH Data Will Shape Outlook
Neurocrine Biosciences' updated analyst price target of $140.00, down from $169.00, reflects refreshed models after Q4 results and 2026 guidance, with analysts still pointing to Ingrezza and Crenessity as key drivers in their long term assumptions despite recent target trims across the Street. Analyst Commentary Street research around Neurocrine Biosciences has turned more mixed, with several bearish analysts trimming price targets following Q4 results and updated 2026 guidance, while a few others have made only modest upward adjustments.ナラティブの更新 • Feb 09
NBIX: Future Returns Will Hinge On Crenessity Execution And Pipeline Delivery
Analysts made a modest trim to their Neurocrine Biosciences price targets, generally landing around the high US$170s. Updated models reflect slightly more conservative revenue growth assumptions and a marginally higher discount rate, partly offset by steady margin expectations and supportive views on Crenessity and Ingrezza.ナラティブの更新 • Jan 24
NBIX: Future Revenue Will Depend On Execution Across Two Key Franchises
Analysts have raised their fair value estimate for Neurocrine Biosciences to about US$204 from US$192. This reflects updated assumptions that include slightly stronger revenue growth, higher profit margins and a lower future P/E multiple after recent Street research refined expectations for Ingrezza, Crenessity and competitor dynamics.ナラティブの更新 • Jan 10
NBIX: Commercial Execution And Pipeline Progress Will Drive Future Shareholder Returns
Analysts have raised their fair value estimate for Neurocrine Biosciences from about $177.92 to $179.66, reflecting updated models that incorporate recent price target revisions, current product performance, and expectations regarding future competition and commercial execution. Analyst Commentary Recent research updates show a mix of optimism and caution around Neurocrine Biosciences, with most price target moves clustering around the high $160s to mid $180s and reflecting updated models on current products, competitive developments in congenital adrenal hyperplasia, and spending to support commercial execution.ナラティブの更新 • Dec 17
NBIX: Advancing CNS Pipeline Readouts Will Drive Future Shareholder Returns
Analysts have modestly increased their average price target for Neurocrine Biosciences by about $3, to roughly $178, citing stronger than expected product performance, sustained Ingrezza growth momentum, and growing confidence in the company’s advancing pipeline despite potential IRA related pricing headwinds. Analyst Commentary Street research remains broadly constructive on Neurocrine, with multiple firms nudging price targets higher as they factor in stronger execution, commercial visibility for Ingrezza and Crenessity, and a maturing late stage pipeline.ナラティブの更新 • Dec 03
NBIX: Late-Stage CNS Pipeline Readouts Will Drive Future Shareholder Value
Analysts have nudged their blended price target for Neurocrine Biosciences modestly higher to the high $170s to low $180s range, reflecting stronger than expected Ingrezza and Crenessity performance, confidence in commercial execution ahead of IRA related headwinds, and growing optimism around the longer term pipeline. Analyst Commentary Bullish analysts largely frame the recent pullback as a mismatch between robust fundamentals and short term market sentiment, with multiple firms lifting price targets into the mid $160s to mid $190s range even as shares consolidated.ナラティブの更新 • Nov 19
NBIX: Late-Stage Pipeline Advancements Will Drive Shareholder Value Amid Industry Headwinds
Neurocrine Biosciences' analyst price target has increased modestly, up by $3 to $174. Analysts cite ongoing strong commercial performance, expanded sales force initiatives, and a robust late-stage pipeline as supporting factors for sustained growth potential.ナラティブの更新 • Nov 05
NBIX: Expanding Commercial Momentum And Pipeline Advances Will Drive Shareholder Value
The analyst price target for Neurocrine Biosciences has been raised from approximately $170 to $175 per share. This reflects analyst optimism about the company’s strong recent earnings, expanded sales efforts, and ongoing commercial and pipeline momentum.ナラティブの更新 • Oct 22
Analysts Boost Neurocrine Biosciences Price Target Citing Strong Revenue Outlook and Clinical Results
Analysts have raised their price target for Neurocrine Biosciences from $168.25 to $169.95. They cite stronger revenue outlooks for key products and supportive recent clinical trial data as the main reasons for this adjustment.Seeking Alpha • Apr 22
Neurocrine Biosciences: Valbenazine As Adjunctive Therapy Could Stage Comeback In 2025
Summary Company's valbenazine shows promise as an adjunctive therapy for Schizophrenia, with phase 3 data expected in 2025, targeting patients unresponsive to antipsychotics. The company also anticipates phase 3 data for valbenazine in treating dyskinetic cerebral palsy in 2025, presenting another market opportunity. Neurocrine's financial health is robust, with $1.8 billion in cash and strong revenue growth from INGREZZA, which saw a 23% year-over-year increase in Q4 2024. The Schizophrenia market across the 7 major markets is expected to reach $17 billion by 2031. Read the full article on Seeking Alpha業績と収益の成長予測
| 日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
|---|---|---|---|---|---|
| 12/31/2028 | 5,010 | 1,408 | 1,757 | 1,864 | 18 |
| 12/31/2027 | 4,476 | 1,090 | 1,376 | 1,424 | 21 |
| 12/31/2026 | 3,773 | 542 | 930 | 717 | 22 |
| 3/31/2026 | 3,102 | 669 | 831 | 864 | N/A |
| 12/31/2025 | 2,861 | 479 | 749 | 783 | N/A |
| 9/30/2025 | 2,683 | 428 | 593 | 637 | N/A |
| 6/30/2025 | 2,510 | 348 | 529 | 567 | N/A |
| 3/31/2025 | 2,413 | 306 | 492 | 530 | N/A |
| 12/31/2024 | 2,355 | 341 | 557 | 595 | N/A |
| 9/30/2024 | 2,243 | 386 | 440 | 476 | N/A |
| 6/30/2024 | 2,120 | 339 | 495 | 530 | N/A |
| 3/31/2024 | 1,982 | 370 | 614 | 645 | N/A |
| 12/31/2023 | 1,887 | 250 | 362 | 390 | N/A |
| 9/30/2023 | 1,784 | 191 | 385 | 409 | N/A |
| 6/30/2023 | 1,673 | 176 | 281 | 296 | N/A |
| 3/31/2023 | 1,599 | 64 | 237 | 255 | N/A |
| 12/31/2022 | 1,489 | 155 | 323 | 339 | N/A |
| 9/30/2022 | 1,389 | 58 | 177 | 201 | N/A |
| 6/30/2022 | 1,297 | 12 | 133 | 164 | N/A |
| 3/31/2022 | 1,208 | 71 | 102 | 129 | N/A |
| 12/31/2021 | 1,134 | 90 | 233 | 257 | N/A |
| 9/30/2021 | 1,069 | 445 | 328 | 347 | N/A |
| 6/30/2021 | 1,032 | 365 | 251 | 265 | N/A |
| 3/31/2021 | 1,045 | 402 | 266 | 280 | N/A |
| 12/31/2020 | 1,046 | 407 | 218 | 229 | N/A |
| 9/30/2020 | 1,042 | 93 | 222 | 232 | N/A |
| 6/30/2020 | 1,006 | 205 | 337 | 350 | N/A |
| 3/31/2020 | 887 | 177 | 283 | 295 | N/A |
| 12/31/2019 | 788 | 37 | N/A | 147 | N/A |
| 9/30/2019 | 675 | 21 | N/A | 100 | N/A |
| 6/30/2019 | 605 | 18 | N/A | 71 | N/A |
| 3/31/2019 | 519 | -39 | N/A | 27 | N/A |
| 12/31/2018 | 451 | 21 | N/A | 101 | N/A |
| 9/30/2018 | 414 | 10 | N/A | 91 | N/A |
| 6/30/2018 | 323 | -52 | N/A | 13 | N/A |
| 3/31/2018 | 233 | -106 | N/A | -55 | N/A |
| 12/31/2017 | 162 | -143 | N/A | -94 | N/A |
| 9/30/2017 | 67 | -194 | N/A | -167 | N/A |
| 6/30/2017 | 6 | -220 | N/A | -188 | N/A |
| 3/31/2017 | N/A | -200 | N/A | -154 | N/A |
| 12/31/2016 | 15 | -141 | N/A | -106 | N/A |
| 9/30/2016 | 15 | -126 | N/A | -90 | N/A |
| 6/30/2016 | 15 | -123 | N/A | -77 | N/A |
| 3/31/2016 | 15 | -107 | N/A | -49 | N/A |
| 12/31/2015 | 20 | -89 | N/A | -38 | N/A |
| 9/30/2015 | 20 | -79 | N/A | -38 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: NBIXの予測収益成長率 (年間23.1% ) は 貯蓄率 ( 3.5% ) を上回っています。
収益対市場: NBIXの収益 ( 23.1% ) はUS市場 ( 18.6% ) よりも速いペースで成長すると予測されています。
高成長収益: NBIXの収益は今後 3 年間で 大幅に 増加すると予想されています。
収益対市場: NBIXの収益 ( 11.8% ) US市場 ( 12.7% ) よりも低い成長が予測されています。
高い収益成長: NBIXの収益 ( 11.8% ) 20%よりも低い成長が予測されています。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: NBIXの 自己資本利益率 は、3年後には高くなると予測されています ( 20.9 %)
成長企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/06/30 22:28 |
| 終値 | 2026/06/30 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Neurocrine Biosciences, Inc. 22 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。39
| アナリスト | 機関 |
|---|---|
| Martha Freitag | Argus Research Company |
| Brian Skorney | Baird |
| Aydin Huseynov | Benchmark Company |